University of Colorado, Denver - Recruiting 18 years or older. - A Phase 2 Study of PF-04449913 for the Treatment of Acute Leukemia Patients With High Risk of Post-Allogeneic Stem Cell Transplantation Relapse.
AstraZeneca - Recruiting 18 years or older. - A Phase Ia/Ib, Open-Label, Multicentre, Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 Administered Daily in Adult Patients With Recurrent or Refractory Acute Myelogenous Leukemia (AML).
Roswell Park Cancer Institute - Recruiting 18 years or older. - A Phase I Study of DEC205mAb-NY ESO 1 Fusion Protein (CDX-1401) Given With Adjuvant polyICLC in Conjunction With 5-Aza-2'Deoxycytidine (Decitabine) in Patients With MDS or Low Blast Count AML.
DEC-205/NY-ESO-1 fusion protein CDX-1401; poly ICLC; decitabine; laboratory biomarker analysis